Greenland Mines Ltd. (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. This development strengthens Greenland Mines’ position in the gene therapy space, particularly as it advances its lead candidates toward clinical trials. Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year.
The issuance of the Canadian patent underscores the global relevance of Klotho gene therapy, a platform that could address significant unmet medical needs in neurodegenerative diseases. With the aging population, conditions like Alzheimer’s and Parkinson’s represent a growing burden on healthcare systems. The patent’s broad claims covering synthesis and delivery methods could provide a competitive advantage in developing therapies that modulate s-KL levels to improve cognitive function and slow disease progression.
Greenland Mines operates two divisions: mining and biotech. The biotech division focuses on Klotho-based therapeutics, with KLTO-202 targeting ALS as a primary indication. The company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
For more details on the patent announcement, the full press release is available at https://ibn.fm/x2pHA. Additional updates on Greenland Mines can be found in the company’s newsroom at https://ibn.fm/GRML.
